Placebo comparator, intramuscular injection, TRI-001
TRI-001-01
Phase 2 small_molecule active
Quick answer
Placebo comparator, intramuscular injection, TRI-001 for Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD) is a Phase 2 program (small_molecule) at Ferring Pharmaceuticals A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ferring Pharmaceuticals A/S
- Indication
- Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active